New option for two rheumatology conditions

Patients with severe psoriatic arthritis and active ankylosing spondylitis have improved treatment choices with the PBS listing of the biologic secukinumab.

Marketed as Cosentyx, the interleukin-17A inhibitor has been listed for the two conditions where response to conventional DMARD therapy has proven inadequate.

Its initial listing in September last year was for patients with plaque psoriasis only.